Clinical Data IDEAYA/Servier PKC drug aces uveal melanoma trial PharmaphorumServier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaphorum Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026. Clinical DataOncologyRead full story Post navigation Previous: AbbVie enters world of pain in up to $715M deal with China’s HaiscoNext: IDEAYA and Servier’s eye cancer drug heads to FDA after delivering ‘best in class’ efficacy Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
